tradingkey.logo
tradingkey.logo
Search

Halozyme Therapeutics Inc

HALO
Add to Watchlist
112.450USD
+2.770+2.53%
Close 09-18 16:00ET
12.84BMarket Cap
38.10P/E TTM

Halozyme Therapeutics Inc (HALO) Revenue Performance

Updated: Jun 30, 2026

Last year, Halozyme Therapeutics Inc generated 867.84M USD for its biggest-performing segment, Royalties. The United States made the largest contribution, accounting for 822.98M USD last year.

By Business

Annual
Annual
Quarterly
Royalties
Sales of proprietary products
Sales of bulk rHuPH20
Sales-based milestones
Sales of device partnered products
Event-based development and regulatory milestones and other fees
Upfront license fees
Device Licensing and development revenue
ENHANZE
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Royalties
867.84M(62.14%)
570.99M(56.24%)
447.87M(54.01%)
360.48M(54.61%)
203.90M(45.99%)
88.60M(33.11%)
69.90M(35.66%)
Sales of proprietary products
194.61M(13.93%)
166.62M(16.41%)
130.83M(15.78%)
72.85M(11.04%)
23.26M(5.25%)
17.03M(6.36%)
17.00M(8.67%)
Sales of bulk rHuPH20
133.02M(9.52%)
86.33M(8.50%)
115.44M(13.92%)
82.08M(12.43%)
80.96M(18.26%)
38.24M(14.29%)
48.28M(24.64%)
Sales-based milestones
70.00M(5.01%)
30.00M(2.95%)
--(--)
10.00M(1.51%)
50.00M(11.28%)
15.00M(5.61%)
--(--)
Sales of device partnered products
48.81M(3.50%)
50.54M(4.98%)
54.58M(6.58%)
36.10M(5.47%)
--(--)
--(--)
--(--)
Event-based development and regulatory milestones and other fees
47.00M(3.37%)
72.50M(7.14%)
69.00M(8.32%)
59.00M(8.94%)
42.00M(9.47%)
69.50M(25.97%)
5.50M(2.81%)
Upfront license fees
18.47M(1.32%)
27.00M(2.66%)
2.00M(0.24%)
30.00M(4.54%)
42.00M(9.47%)
37.26M(13.93%)
53.00M(27.04%)
Device Licensing and development revenue
16.86M(1.21%)
11.34M(1.12%)
9.53M(1.15%)
9.61M(1.46%)
1.19M(0.27%)
1.25M(0.47%)
1.54M(0.79%)
ENHANZE
--(--)
--(--)
--(--)
--(--)
--(--)
719.00K(0.27%)
768.00K(0.39%)

By Region

Annual
Annual
Quarterly
United States
Switzerland
Belgium
Japan
All other foreign
United States
Switzerland
Belgium
Ireland
FY2025
FY2024
FY2023
FY2022
United States
822.98M(58.93%)
--(--)
--(--)
--(--)
Switzerland
276.41M(19.79%)
--(--)
--(--)
--(--)
Belgium
217.52M(15.57%)
--(--)
--(--)
--(--)
Japan
46.37M(3.32%)
18.94M(1.87%)
15.10M(1.82%)
47.94M(7.26%)
All other foreign
33.33M(2.39%)
9.53M(0.94%)
19.58M(2.36%)
5.26M(0.80%)
United States
--(--)
690.46M(68.00%)
587.20M(70.81%)
437.99M(66.35%)
Switzerland
--(--)
212.39M(20.92%)
149.02M(17.97%)
166.84M(25.27%)
Belgium
--(--)
84.00M(8.27%)
58.35M(7.04%)
2.09M(0.32%)
Ireland
--(--)
--(--)
--(--)
3.00K(--)
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.